{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:53:30Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0953f-0bba-76a0-99c0-e46e96345e0e\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: lasmiditan\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 79.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0953f-0bad-7c40-84d4-71c4ce27361f\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: lasmiditan\nRegistry id: vr.tr.lasmiditan\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:50:27+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q6493750", "registryId": "vr.tr.lasmiditan", "name": "lasmiditan", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q6493750/", "model": { "registry_id": "vr.tr.lasmiditan", "name": "lasmiditan", "purpose": "Enable an agent to identify lasmiditan, assess the identity and condition of a material sample, and determine which handling or use decisions require additional evidence.", "definition": "Lasmiditan is a small-molecule, centrally acting, selective serotonin 5-HT1F receptor agonist used for the acute treatment of migraine with or without aura in adults.", "scope_statement": "This model owns the chemical identity of lasmiditan under vr.tr.lasmiditan in PHY / PHY.MAT, including material quality, form-dependent properties, pharmacological capabilities, and constraints; salts and formulated medicines are linked entities whose properties must not be silently attributed to the parent substance.", "in_scope": [ "Lasmiditan molecular identity and verified identifiers", "Relationships between the parent substance, salt forms, and active-moiety quantities", "Sample composition, purity, impurities, and analytical identity", "Physical state, measured properties, stability, and storage conditions", "Receptor activity and evidence-linked handling and use constraints" ], "out_of_scope": [ "Finished tablet formulations, excipients, packaging, and brand identities", "Individual migraine diagnosis and patient-specific prescribing", "Manufacturing processes and their operational control", "The serotonin receptor family as a biological system", "Clinical trial operations and population-level migraine management" ], "distinguishing_features": [ "Match the parent molecular structure to formula C19H18F3N3O2, CAS 439239-90-4, and PubChem CID 11610526; a name match alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Lasmiditan)", "Distinguish parent lasmiditan from lasmiditan hemisuccinate by counterion identity and stoichiometry; the FDA label identifies hemisuccinate as the form used in the described tablets. [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211280s008lbl.pdf)", "Check evidence for selective serotonin 5-HT1F agonism when distinguishing lasmiditan from other migraine-active compounds; therapeutic indication alone does not establish identity. [IUPHAR/BPS](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3928&tab=summary)", "Distinguish an isolated lasmiditan material from a formulated medicine by its complete composition and the basis on which its lasmiditan content is expressed." ], "characteristics": [ { "name": "Parent molecular identity", "kind": "category", "unit_or_values": "Structure identifier; C19H18F3N3O2; CAS 439239-90-4; PubChem CID 11610526", "why_it_matters": "Provides the identity anchor against which salts, aliases, and analytical results are checked. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Lasmiditan)" }, { "name": "Material form", "kind": "category", "unit_or_values": "Parent substance, specified salt, hydrate or solvate if demonstrated, mixture, or unresolved", "why_it_matters": "Controls which molecular mass, physical properties, and analytical specifications apply." }, { "name": "Counterion relationship", "kind": "relation", "unit_or_values": "Counterion identity and molar ratio to lasmiditan", "why_it_matters": "Prevents a salt quantity from being interpreted directly as the same mass of lasmiditan." }, { "name": "Lasmiditan assay", "kind": "measurement", "unit_or_values": "% w/w or mg/g; specify as-is, dry, salt, or parent-equivalent basis", "why_it_matters": "Makes reported content interpretable across materials with different counterion and water contents." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual and total impurities in % or ppm, with method and reporting limits", "why_it_matters": "Supports assessment of degradation, contamination, and fitness for an intended use." }, { "name": "Solid form and thermal behavior", "kind": "state", "unit_or_values": "Observed phase; crystalline-form evidence; melting or decomposition event in °C with method", "why_it_matters": "Distinguishes material changes that may affect dissolution, assay interpretation, or stability." }, { "name": "Solubility", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent, pH, temperature, and material form", "why_it_matters": "Determines whether preparation and analytical conditions can produce the intended dissolved concentration." }, { "name": "Receptor activity", "kind": "measurement", "unit_or_values": "5-HT1F binding affinity and functional potency in nM, with assay system and comparator receptors", "why_it_matters": "Separates molecular identity from measured pharmacological performance and selectivity." }, { "name": "Stability disposition", "kind": "state", "unit_or_values": "Within supported retest period, excursion under assessment, degraded, or unknown", "why_it_matters": "Links present usability to storage history and evidence rather than appearance alone." }, { "name": "Regulatory and hazard applicability", "kind": "category", "unit_or_values": "Jurisdiction, effective date, material form, intended use, applicable classification, and evidence", "why_it_matters": "Keeps pharmaceutical warnings, workplace hazards, and legal controls distinct and current." } ], "affordances": [ "Resolve a named or labelled material to lasmiditan using structural and analytical evidence.", "Calculate parent-equivalent content from a verified salt composition and assay basis.", "Compare a lot against documented identity, purity, and stability requirements.", "Select evidence-supported dissolution, sampling, and storage conditions for the identified material form.", "Link receptor-activity evidence and medicinal safety constraints to a proposed use without generating patient-specific treatment instructions.", "Flag unresolved identity, quality, or jurisdictional constraints before releasing material for an intended use." ], "agent_conduct": { "may": [ "Identify lasmiditan by name, identifiers and documented properties, citing sources.", "Report approved uses, warnings and controlled status from official product information.", "Check a material lot's certificate of analysis against its specification." ], "must_not": [ "Recommend it or a dose for a particular person's migraine.", "Advise someone that it is safe to drive or operate machinery after taking it.", "Supply it outside lawful pharmaceutical channels.", "Present it as a preventive treatment when it is for acute attacks." ], "requires_human": [ "Any decision to start or change a patient's migraine treatment.", "Releasing or destroying a material lot." ] }, "ethics": { "considerations": [ "Migraine is disabling and often dismissed; honest information supports patients.", "Central effects such as dizziness and sedation put the patient and others at risk on the road." ], "affected_parties": [ "People with migraine", "Other road users", "Prescribers" ] }, "owners": { "steward": "The marketing authorization holder for each medicine; the national medicines regulator oversees it.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity rests on the label, batch record and certificate of analysis, not appearance.", "Product packs state it is for acute migraine treatment." ], "failure_modes_and_hazards": [ "Dizziness and sedation that can impair driving.", "Overuse of acute migraine medicines can worsen headaches.", "Misuse potential has led to controlled status in some countries." ], "standards_and_regulation": [ "ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation." ], "what_it_is_for": [ "This compound is encountered as an active pharmaceutical ingredient for the acute treatment of migraine in adults.", "It is also used in pharmaceutical analysis and research on serotonin receptor activity, metabolism and medicine quality." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q6493750: lasmiditan", "url": "https://www.wikidata.org/wiki/Q6493750", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Lasmiditan", "url": "https://en.wikipedia.org/wiki/Lasmiditan", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "molecular-identity-and-form", "name": "Molecular identity and form", "description": "Recognize lasmiditan and preserve the distinction between its parent identity and supplied chemical form.", "rationale": "A lasmiditan name can refer to an active moiety even when the physical material contains a counterion.", "layers": [ { "id": "parent-identity", "name": "Parent identity", "description": "Anchor identifiers and aliases to the same molecular structure.", "findings": [ { "id": "structure-identifier-agreement", "name": "Structure and identifier agreement", "description": "Require agreement between the claimed lasmiditan identity, a structure-resolved reference, and sample evidence.", "questions": [ { "text": "Which verified structure and identifiers define lasmiditan for this record?", "kind": "definition", "id": "structure-identifier-agreement-q01" }, { "text": "Which reference standard and analytical results support identifying this sample as lasmiditan?", "kind": "provenance", "id": "structure-identifier-agreement-q02" } ] } ] }, { "id": "salt-and-moiety-boundary", "name": "Salt and moiety boundary", "description": "Record counterions and distinguish total material mass from lasmiditan content.", "findings": [ { "id": "hemisuccinate-content-basis", "name": "Hemisuccinate and content basis", "description": "Represent hemisuccinate through an explicit relationship to lasmiditan, retaining the measured composition and quantity basis.", "questions": [ { "text": "Is this material parent lasmiditan, hemisuccinate, another demonstrated form, or a formulation containing it?", "kind": "boundary", "id": "hemisuccinate-content-basis-q01" }, { "text": "What counterion ratio, water content, and assay basis are needed to calculate lasmiditan-equivalent mass?", "kind": "measurement", "id": "hemisuccinate-content-basis-q02" } ] } ] } ] }, { "id": "composition-and-quality", "name": "Composition and quality", "description": "Assess whether a lasmiditan lot has the identity and composition required for its intended use.", "rationale": "Identity alone does not establish assay strength, impurity acceptability, or suitability as a pharmaceutical or research material.", "layers": [ { "id": "assay-and-reference", "name": "Assay and reference", "description": "Interpret quantified lasmiditan content against a qualified reference.", "findings": [ { "id": "interpretable-lasimiditan-assay", "name": "Interpretable lasmiditan assay", "description": "Keep chromatographic purity, mass-based content, and parent-equivalent assay separate.", "questions": [ { "text": "Does the reported result measure chromatographic area purity, total mass fraction, or lasmiditan-equivalent content?", "kind": "measurement", "id": "interpretable-lasimiditan-assay-q01" }, { "text": "Which reference standard, qualification record, and analytical method support that result?", "kind": "provenance", "id": "interpretable-lasimiditan-assay-q02" } ] } ] }, { "id": "impurities-and-disposition", "name": "Impurities and disposition", "description": "Evaluate non-lasmiditan constituents and their consequences for material release.", "findings": [ { "id": "lot-fitness", "name": "Lot fitness", "description": "Assess related substances, residual solvents, water, and other relevant contaminants against an applicable specification.", "questions": [ { "text": "Which impurities are identified or unresolved, and what are their measured amounts and reporting limits?", "kind": "measurement", "id": "lot-fitness-q01" }, { "text": "Does the lot meet a documented specification for the proposed use, or should it remain under assessment?", "kind": "action", "id": "lot-fitness-q02" } ] } ] } ] }, { "id": "physical-behavior-and-stability", "name": "Physical behavior and stability", "description": "Connect lasmiditan material form to dissolution, thermal behavior, and preservation.", "rationale": "Properties measured for a salt, solvent system, or formulated tablet cannot automatically characterize every lasmiditan sample.", "layers": [ { "id": "form-dependent-properties", "name": "Form-dependent properties", "description": "Record physical measurements with enough conditions to make them transferable.", "findings": [ { "id": "phase-and-dissolution-evidence", "name": "Phase and dissolution evidence", "description": "Bind phase, thermal events, and solubility measurements to the tested lasmiditan form.", "questions": [ { "text": "Which solid form was tested, and does the reported thermal event represent melting, desolvation, or decomposition?", "kind": "measurement", "id": "phase-and-dissolution-evidence-q01" }, { "text": "What solubility was measured at the stated solvent composition, pH, temperature, and equilibration time?", "kind": "measurement", "id": "phase-and-dissolution-evidence-q02" } ] } ] }, { "id": "storage-and-degradation", "name": "Storage and degradation", "description": "Judge whether handling history has compromised the material.", "findings": [ { "id": "supported-storage-disposition", "name": "Supported storage disposition", "description": "Use form-specific stability evidence and actual exposure history to determine continued usability.", "questions": [ { "text": "Which stability study supports the storage conditions and retest period for this lasmiditan material?", "kind": "provenance", "id": "supported-storage-disposition-q01" }, { "text": "After the recorded temperature, moisture, or light exposure, what reassessment is required before use?", "kind": "action", "id": "supported-storage-disposition-q02" } ] } ] } ] }, { "id": "pharmacological-capability", "name": "Pharmacological capability", "description": "Represent lasmiditan's receptor activity and its relationship to medicinal effects.", "rationale": "Receptor selectivity helps distinguish lasmiditan, while clinical claims require evidence beyond a binding assay.", "layers": [ { "id": "receptor-pharmacology", "name": "Receptor pharmacology", "description": "Separate receptor binding from functional agonism and comparative selectivity.", "findings": [ { "id": "serotonin-1f-activity", "name": "Serotonin 1F activity", "description": "Capture evidence for 5-HT1F agonism with assay context and measured comparator activity.", "questions": [ { "text": "Which binding and functional assays establish lasmiditan activity at human 5-HT1F receptors?", "kind": "provenance", "id": "serotonin-1f-activity-q01" }, { "text": "How does activity compare with 5-HT1B and 5-HT1D under comparable assay conditions?", "kind": "measurement", "id": "serotonin-1f-activity-q02" } ] } ] }, { "id": "clinical-evidence-boundary", "name": "Clinical evidence boundary", "description": "Link medicinal evidence without treating the substance as a complete treatment decision.", "findings": [ { "id": "substance-to-treatment-link", "name": "Substance-to-treatment link", "description": "Associate clinical claims with the studied formulation, exposure, population, and endpoint.", "questions": [ { "text": "Which formulation and clinical evidence support the claimed migraine-related effect?", "kind": "provenance", "id": "substance-to-treatment-link-q01" }, { "text": "Which conclusions concern lasmiditan itself, and which depend on a medicine, administration regimen, or patient population?", "kind": "boundary", "id": "substance-to-treatment-link-q02" } ] } ] } ] }, { "id": "safety-and-permitted-use", "name": "Safety and permitted use", "description": "Connect lasmiditan-specific safety evidence and legal status to the proposed activity.", "rationale": "Medicinal exposure warnings, bulk-material hazards, and jurisdictional controls answer different operational questions.", "layers": [ { "id": "exposure-and-safety", "name": "Exposure and safety", "description": "Keep clinical impairment evidence distinct from occupational exposure classification.", "findings": [ { "id": "exposure-specific-constraints", "name": "Exposure-specific constraints", "description": "The cited FDA label identifies driving impairment, central nervous system depression, and serotonin syndrome warnings; their application must remain tied to medicinal exposure evidence. [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211280s008lbl.pdf)", "questions": [ { "text": "Which current medicinal warnings and interaction evidence apply to the contemplated use?", "kind": "action", "id": "exposure-specific-constraints-q01" }, { "text": "Which material-specific safety data sheet, GHS classification, and exposure-control evidence govern handling of this lot?", "kind": "provenance", "id": "exposure-specific-constraints-q02" } ] } ] }, { "id": "jurisdiction-and-authority", "name": "Jurisdiction and authority", "description": "Determine whether a proposed acquisition, transfer, or use is supported by current authoritative records.", "findings": [ { "id": "dated-legal-applicability", "name": "Dated legal applicability", "description": "Record legal classifications separately from product authorization and actual market availability.", "questions": [ { "text": "Which dated official records establish the controls applicable to lasmiditan and this material form in the relevant jurisdiction?", "kind": "provenance", "id": "dated-legal-applicability-q01" }, { "text": "What conditions must the proposed acquisition, storage, transfer, or use satisfy?", "kind": "action", "id": "dated-legal-applicability-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is a recall-based description; no sources were consulted.", "Verify current jurisdiction-specific authorization, availability, controlled-substance status and prescribing information.", "Confirm salt-specific registry identifiers, purity specifications, physical constants and chemical hazard classifications before populating material records." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of lasmiditan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Lasmiditan free base", "Lasmiditan succinate, the pharmaceutical salt form" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of lasmiditan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "lasmiditan", "note": "Names the active substance rather than a finished medicine." }, { "scheme": "Drug development code", "value_or_pattern": "LY573144", "note": "Development identifier for lasmiditan." }, { "scheme": "US proprietary drug name", "value_or_pattern": "Reyvow", "note": "Identifies a formulated medicine containing lasmiditan as its succinate salt." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of lasmiditan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "US Food and Drug Administration: approved Reyvow in 2019 for acute treatment of migraine with or without aura in adults." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of lasmiditan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Oral treatment of an acute migraine attack in adults." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of lasmiditan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Driving impairment and sedation; US prescribing information specifies avoiding driving or operating machinery for at least eight hours after a dose.", "Dizziness, fatigue and sensory disturbances can occur.", "Concurrent alcohol or other central nervous system depressants can increase impairment.", "Serotonin syndrome is a labeled risk, including with concurrent serotonergic medicines.", "Frequent use of acute migraine medicines can contribute to medication-overuse headache." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of lasmiditan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Triptans", "difference": "Triptans principally target 5-HT1B/1D receptors; lasmiditan targets 5-HT1F and lacks the 5-HT1B-mediated vasoconstrictive mechanism." }, { "name": "Gepants", "difference": "Gepants antagonize the calcitonin gene-related peptide receptor rather than activating 5-HT1F receptors." }, { "name": "Lasmiditan succinate", "difference": "The succinate is a salt containing the lasmiditan active moiety and a counterion, with a distinct composition from the free base." }, { "name": "Reyvow tablets", "difference": "The finished product contains a specified amount of active ingredient plus excipients; it is not identical to the isolated chemical substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of lasmiditan this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does the wider Vercy catalogue already contain an authoritative model covering lasmiditan, and how should hemisuccinate be linked without duplicating the parent concept?", "Which validated specifications and impurity reference standards apply to the intended lasmiditan grade?", "What measured solid-form, solubility, melting or decomposition, and stability data are available separately for the parent substance and hemisuccinate?", "Which EC identifiers, material-specific GHS classifications, and occupational exposure limits are authoritatively established, and which remain unavailable?", "What are the current jurisdiction-specific controls, medicine authorizations, and availability, and which primary studies best establish receptor selectivity and its clinical interpretation?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 27 } }